WebDescription: INCB053914, also known as Uzansertib, is a novel, potent, and selective adenosine triphosphate-competitive pan-PIM kinase inhibitor. In vitro, INCB053914 … WebUzansertib (INCB053914) is a novel, ATP-competitive, small molecule, pan-inhibitor of PIM kinases with IC50 values of 0.24 nM, 30 nM and 0.12 nM for PIM1, PIM2 and PIM3 …

Study of INCB053914 in Subjects With Advanced Malignancies

WebINCB053914 (INCB-053914) is a novel potent, and selective ATP-competitive, pan-PIM kinase inhibitor with IC50 of 0.24/30.0/0.12 nM for PIM1/2/3, respectively; INCB053914 is highly selective against a panel of more than 50 kinases (>475-fold selectivity) with exception of RSK2 (IC50=7.1 uM); inhibits cellular proliferation in a panel of cell lines … WebUzansertib (INCB053914) phosphate is an orally active, ATP-competitive pan- PIM kinase inhibitor with IC50 s of 0.24 nM, 30 nM, 0.12 nM for PIM1, PIM2, PIM3, respectively. … small plates edinburgh

Massachusetts Board of Registration in Pharmacy

WebEffects of the selective PI3Kδ inhibitor, INCB050465, on PIM isozyme expression in Pfeiffer DLBCL cells (A). Effects of INCB053914 alone, or in combination with INCB050465, on the in vitro proliferation of Pfeiffer DLBCL cells (B). Effects of INCB053914 alone or in combination with INCB050465 on tumor growth in a DLBCL xenograft model (C); with cytarabine on … WebINCB053914 phosphate is an inhibitor of Pim extracted from patent WO 2024044730 A1, compound 1; has an IC50 of less than 35 nM. Availability: In stock Free Overnight Delivery … WebINCB053914 is active as a single agent in the majority of cell lines derived from different hematological malignancies, including MM, AML, DLBCL, MCL and T-ALL, with IC50 … highlights for kids/hidden pictures printable